Drugs /

pf-07284892

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for pf-07284892

Pf-07284892 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pf-07284892, 1 is phase 1 (1 open).

ALK Fusion, BRAF D287H, and BRAF D594A are the most frequent biomarker inclusion criteria for pf-07284892 clinical trials.

Colorectal carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in pf-07284892 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pf-07284892
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pf-07284892 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pf07284892

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.